Theravance Biopharma (Theravance Biopharma) Valuation Rank

View and export this data going back to 2014. Start your Free Trial

What is Theravance Biopharma Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Theravance Biopharma Valuation Rank Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Theravance Biopharma (Theravance Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (NAS:TBPH) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

0TB:Germany

Address

Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104

Website

https://www.theravance.com

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Executives

Rhonda Farnum	officer: SVP, Comm & Medical Affairs	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Richard A Graham	officer: SVP, Development	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kelly James Connor	director	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Susannah Gray	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Brett A. Grimaud	officer: SVP, Gen Counsel and Secretary	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Aziz Sawaf	officer: SVP & Chief Financial Officer	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Rick E Winningham	director, officer: Chief Executive Officer	901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Andrew A. Hindman	officer: SVP, Chief Financial Officer	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Eli Samaha	10 percent owner	ONE WORLD TRADE CENTER, FLOOR 65, NEW YORK NY 10007
Wam Gp Llc	10 percent owner	222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Andrew M Weiss	10 percent owner	222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Weiss Asset Management Lp	10 percent owner	222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Philip D Worboys	officer: SVP, Translational Science	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Brett K Haumann	officer: VP-Clinical Develop.	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Deepika Pakianathan	director	160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402